Compare Stocks: MDCX, LONA, ZYBT, and SPRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LONA Athira Pharma	$7.98 +1.4%	$8.26	$3.52 ▼ $14.21	$73.93M	2.04	14,814 shs	9,289 shs
MDCX Medicus Pharma	$0.28 -20.9%	$0.37	$0.25 ▼ $3.05	$22.37M	0.11	1.60 million shs	2.69 million shs
SPRO Spero Therapeutics	$1.23 -0.8%	$1.83	$1.08 ▼ $3.08	$71.80M	1.55	1.74 million shs	744,544 shs
ZYBT Zhengye Biotechnology	$1.56 +2.0%	$1.25	$0.62 ▼ $13.08	$72.51M	-2.72	16.15 million shs	176,589 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LONA Athira Pharma	0.00%	+0.77%	-17.33%	-30.11%	+786,999,900.00%
MDCX Medicus Pharma	+6.92%	+15.08%	-2.69%	+17.61%	-83.14%
SPRO Spero Therapeutics	+4.20%	-2.36%	-27.06%	-55.56%	-35.75%
ZYBT Zhengye Biotechnology	-1.29%	-26.79%	+115.34%	+60.66%	-81.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LONA Athira Pharma	$7.98 +1.4%	$8.26	$3.52 ▼ $14.21	$73.93M	2.04	14,814 shs	9,289 shs
MDCX Medicus Pharma	$0.28 -20.9%	$0.37	$0.25 ▼ $3.05	$22.37M	0.11	1.60 million shs	2.69 million shs
SPRO Spero Therapeutics	$1.23 -0.8%	$1.83	$1.08 ▼ $3.08	$71.80M	1.55	1.74 million shs	744,544 shs
ZYBT Zhengye Biotechnology	$1.56 +2.0%	$1.25	$0.62 ▼ $13.08	$72.51M	-2.72	16.15 million shs	176,589 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LONA Athira Pharma	0.00%	+0.77%	-17.33%	-30.11%	+786,999,900.00%
MDCX Medicus Pharma	+6.92%	+15.08%	-2.69%	+17.61%	-83.14%
SPRO Spero Therapeutics	+4.20%	-2.36%	-27.06%	-55.56%	-35.75%
ZYBT Zhengye Biotechnology	-1.29%	-26.79%	+115.34%	+60.66%	-81.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LONA Athira Pharma	2.50	Moderate Buy	$16.00	100.50% Upside
MDCX Medicus Pharma	2.40	Hold	$9.00	3,113.14% Upside
SPRO Spero Therapeutics	2.00	Hold	N/A	N/A
ZYBT Zhengye Biotechnology	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest MDCX, LONA, ZYBT, and SPRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/7/2026	LONA Athira Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/30/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$18.00
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/20/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
7/17/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	MDCX Medicus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/11/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
5/29/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
5/27/2026	LONA Athira Pharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$20.00
5/15/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LONA Athira Pharma	N/A	N/A	N/A	N/A	$2.98 per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	($0.03) per share	N/A
SPRO Spero Therapeutics	$42.96M	1.66	$0.15 per share	8.15	$0.76 per share	1.62
ZYBT Zhengye Biotechnology	$16.64M	4.44	N/A	N/A	$0.93 per share	1.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LONA Athira Pharma	-$105.61M	-$5.21	N/A	N/A	N/A	N/A	-381.01%	-225.74%	N/A
MDCX Medicus Pharma	-$35.46M	-$2.68	N/A	N/A	N/A	N/A	-16,319.59%	-263.24%	N/A
SPRO Spero Therapeutics	$8.57M	$0.11	11.18	N/A	N/A	24.90%	16.17%	12.57%	N/A
ZYBT Zhengye Biotechnology	-$9.98M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest MDCX, LONA, ZYBT, and SPRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	LONA Athira Pharma	-$1.90	-$0.80	+$1.10	-$0.80	N/A	N/A
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$0.1275	-$0.21	-$0.0825	-$0.21	N/A	N/A
8/12/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	-$0.16	+$0.01	-$0.16	N/A	N/A
5/14/2026	Q1 2026	MDCX Medicus Pharma	-$0.18	-$0.31	-$0.13	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	$0.06	4.88%	N/A	54.55%	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LONA Athira Pharma	N/A	10.38	10.38
MDCX Medicus Pharma	N/A	1.57	1.22
SPRO Spero Therapeutics	N/A	6.12	10.50
ZYBT Zhengye Biotechnology	0.03	1.14	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LONA Athira Pharma	57.12%
MDCX Medicus Pharma	N/A
SPRO Spero Therapeutics	25.60%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
LONA Athira Pharma	25.73%
MDCX Medicus Pharma	8.10%
SPRO Spero Therapeutics	2.90%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LONA Athira Pharma	40	9.39 million	6.98 million	No Data
MDCX Medicus Pharma	N/A	63.18 million	52.07 million	N/A
SPRO Spero Therapeutics	150	57.90 million	56.22 million	Optionable
ZYBT Zhengye Biotechnology	278	47.39 million	N/A	N/A

MDCX, LONA, ZYBT, and SPRO Headlines

Recent News About These Companies

Zhengye Biotechnology Regains Nasdaq Minimum Bid Price Compliance

August 6, 2026 | tipranks.com

Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today

August 5, 2026 | quiverquant.comQ

Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | Benzinga

July 23, 2026 | benzinga.com

Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity

July 21, 2026 | tipranks.com

Zhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)

July 21, 2026 | msn.com

Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity

July 21, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

July 21, 2026 | globenewswire.com

Why Zhengye Biotechnology Holding Limited (ZYBT) Stock Is Up Today

July 20, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Ltd. Class A

July 13, 2026 | cnn.com

Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice

June 4, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

June 4, 2026 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

April 28, 2026 | prnewswire.com

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026

April 6, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

April 6, 2026 | globenewswire.com

Zhengye Biotechnology Holding Ltd ZYBT

March 28, 2026 | morningstar.comM

Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM

March 25, 2026 | tipranks.com

Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM

February 23, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

February 11, 2026 | markets.businessinsider.com

Zhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder Letter

February 10, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders

February 10, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX, LONA, ZYBT, and SPRO Company Descriptions

Athira Pharma NASDAQ:LONA

$7.98 +0.11 (+1.40%)

Closing price 03:58 PM Eastern

Extended Trading

$7.97 -0.01 (-0.08%)

As of 07:58 PM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Medicus Pharma NASDAQ:MDCX

$0.28 -0.07 (-20.88%)

Closing price 04:00 PM Eastern

Extended Trading

$0.28 0.00 (-0.04%)

As of 07:59 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Spero Therapeutics NASDAQ:SPRO

$1.23 -0.01 (-0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$1.23 0.00 (-0.33%)

As of 07:55 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Zhengye Biotechnology NASDAQ:ZYBT

$1.56 +0.03 (+1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$1.56 +0.00 (+0.32%)

As of 07:56 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDCX, LONA, ZYBT, and SPRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDCX, LONA, ZYBT, and SPRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDCX, LONA, ZYBT, and SPRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX, LONA, ZYBT, and SPRO Company Descriptions

Athira Pharma NASDAQ:LONA

Medicus Pharma NASDAQ:MDCX

Spero Therapeutics NASDAQ:SPRO

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDCX, LONA, ZYBT, and SPRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDCX, LONA, ZYBT, and SPRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDCX, LONA, ZYBT, and SPRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX, LONA, ZYBT, and SPRO Company Descriptions

Athira Pharma NASDAQ:LONA

Medicus Pharma NASDAQ:MDCX

Spero Therapeutics NASDAQ:SPRO

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools